Compare LMND & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | IDYA |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.6B |
| IPO Year | 2020 | 2019 |
| Metric | LMND | IDYA |
|---|---|---|
| Price | $53.41 | $39.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | ★ $70.86 | $52.86 |
| AVG Volume (30 Days) | ★ 875.2K | 658.3K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.40 | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $737,900,000.00 | $218,710,000.00 |
| Revenue This Year | $65.20 | N/A |
| Revenue Next Year | $33.31 | $201.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 40.15 | ★ 3024.43 |
| 52 Week Low | $46.16 | $23.23 |
| 52 Week High | $99.90 | $42.68 |
| Indicator | LMND | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 56.57 |
| Support Level | $51.57 | $33.57 |
| Resistance Level | $56.71 | $39.93 |
| Average True Range (ATR) | 1.96 | 1.41 |
| MACD | 0.56 | -0.06 |
| Stochastic Oscillator | 78.36 | 56.40 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.